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Abstract: 
Background: Rituximab (RTX) is approved for remission induction in ANCA associated 
vasculitis (AAV). However, data on use of RTX in patients with severe renal disease is 
lacking. 
Methods: We conducted a retrospective multi-center study to evaluate the efficacy and 
safety of RTX with glucocorticoids (GC) with and without use of concomitant 
cyclophosphamide (CYC) for remission induction in patients presenting with e GFR less 
than 20 ml/min/1.73 m2. We evaluated outcomes of remission at 6 months (6M), renal 
recovery after acute dialysis at diagnosis, e-GFR rise at 6M, patient and renal survival 
and adverse events.  
Results: A total 37 patients met the inclusion criteria. The median age was 61 yrs. (55 
to 73), 62% were males, 78% had new diagnosis and 59% were MPO ANCA positive. 
The median (IQR) e-GFR at diagnosis was 13 ml/min/1.73 m2 (7 to 16) and 15 required 
acute dialysis. Eleven (30%) had alveolar hemorrhage. Twelve (32 %) received RTX 
with GC, 25 (68 %) received RTX with GC and CYC and seventeen (46%) received 
plasma exchange. The median (IQR) follow up was 973 (200 to 1656) days. Thirty two 
of 33 patients (97%) achieved remission at 6 M and 10 of 15 patients (67%) requiring 
dialysis recovered renal function. The median prednisone dose at 6M was 6 mg/day. 
The mean (SD) increase in e-GFR at 6 months was 14.5 (22) ml/min/m2.  Twelve 
patients developed ESRD during follow up. There were 3 deaths in the first 6 months.  
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When stratified by use of concomitant CYC, there were no differences in baseline e 
GFR, use of plasmapheresis, RTX dosing regimen or median follow up days between 
the groups. No differences in remission, renal recovery ESRD or death were observed. 
Conclusions:  
This study of AAV patients with severe renal disease demonstrates that the outcomes 
appear equivalent when treated with RTX and GC with or without concomitant CYC. 
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Introduction: 
Rapidly progressive glomerulonephritis and diffuse pulmonary hemorrhage are the most 
common severe disease manifestations of ANCA associated small vessel vasculitis 
(AAV). Renal involvement occurs in 20- 50% of patients at disease onset and in 70-80% 
of patients during the disease course. Immunosuppressive therapy is indicated even in 
patients with severe renal disease requiring dialysis at diagnosis as there has never 
been a report that clinical features or histologic features of disease presentation could 
demonstrate a “point of no return” where immunosuppression is considered futile(1).  
Published reports note that 55 to 90% of initially dialysis dependent AAV patients 
recover enough renal function to discontinue dialysis (1-4). Both morbidity and mortality 
are high in patients who remain dialysis dependent, with both age greater than 60 years 
and renal dysfunction associated with poor prognosis(5). Progression to end stage renal 
disease (ESRD) can be prevented by prompt diagnosis and timely initiation of therapy. 
Induction therapy with glucocorticoids and cyclophosphamide with or without plasma 
exchange is the standard therapy and is usually effective with greater than 90% of 
patients achieving remission. However, 50% of patients will relapse. In these relapsing 
patients, the cost of remission is substantial with 42% of patients developed some form 
of serious morbidity directly attributable to therapy(6). Despite strategies to minimize 
exposure to cyclophosphamide, analysis of recent trials show that 59% of early mortality 
in AAV is attributable to therapy related events(7). The anti-CD20 monoclonal antibody 
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rituximab depletes B cells and has been approved for remission induction in AAV (8). 
Fourteen studies have examined rituximab use for remission induction(9). The 
remission rates after rituximab have varied from 62 to 90%, with differences in 
remission definitions influencing the results; in particular, the lower response rates were 
observed in the two randomized trials, which employed more stringent remission 
definitions(10, 11). 
 
Patients with severe renal disease were excluded from many of the observational 
studies and from the RAVE trial because insufficient equipoise existed at the launch of 
RAVE trial to justify the randomization of patients with advanced renal dysfunction to an 
investigational treatment (10, 11). The RITUXVAS trial enrolled patients with severe 
renal disease. However, patients randomized to the rituximab arm received two pulses 
of intravenous cyclophosphamide (11). Furthermore, the KDIGO guidelines recommend 
use of rituximab for initial treatment only in absence of severe renal disease(12). The 
purpose of this retrospective multicenter study is to evaluate the efficacy and safety of 
using rituximab for remission induction in patients with AAV and severe renal 
involvement defined as, estimated eGFR less than 20ml/min/m2. This eGFR was 
chosen to represent severe renal disease since patients become eligible to be placed 
on transplant wait list and accrue waiting time once the eGFR is at or below 20 ml/min. 
 
 
Material and Methods: 
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Study Population: 
The study population consisted of patients from a retrospective cohort from six different 
sites in United States and Europe (Johns Hopkins vasculitis center, U.S.A., Columbia 
University, U.S.A., Charles University, Prague, Linkoping University, Sweden, University 
of Birmingham, U.K. and Cambridge University Hospital, U.K.). Patients with a 
diagnosis of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) 
with active glomerulonephritis who met the following inclusion criteria were studied: 1) 
eGFR less than 20 ml/min/m2; 2) remission induction therapy with glucocorticoids and 
rituximab with or without concomitant cyclophosphamide; and 3) follow up until 
remission or death. Patients were allowed to have had plasma exchange. There was no 
set protocol and as such the administration of cyclophosphamide and plasma exchange 
was dependent on the practice pattern of the physicians. The study protocol was 
approved by the Institutional Review Board at each institution 
Data Acquisition: 
Clinical data: 
Demographic and clinical data at the time of diagnosis including age, gender, disease 
phenotype, ANCA type, new versus established diagnosis, clinical features at 
presentation, eGFR at presentation and six months, occurrence of disease relapse, 
need for renal replacement therapy at the time of presentation and at last follow up and 
details of induction immunosuppression including the dosing of rituximab, formulation 
and duration of cyclophosphamide use  and number of sessions of plasmapheresis 
were extracted from review of clinical source documents. Adverse events including 
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rituximab infusion reaction, episodes of leukopenia (WBC less than 4.0) and infections 
requiring hospitalization were recorded.  
 
Laboratory data:  
Peak serum creatinine, erythrocyte sedimentation rate and C - reactive protein at the 
time of diagnosis were recorded.  Available data on urine protein quantification data 
based on a spot urine sample or a 24 hour urine collection at the time of diagnosis was 
recorded. ANCA testing was done by standard indirect immunofluorescence assay on 
ethanol fixed neutrophils for cytoplasmic ANCA (c-ANCA) and perinuclear ANCA (p-
ANCA). PR3 and myeloperoxidase (MPO) testing was done by direct enzyme linked 
immunosorbent assay (ELISA) with commercially available kits at the local lab. If the 
testing for c-ANCA, p-ANCA, PR3 ELISA and MPO ELISA was negative, patients were 
labeled as having ANCA negative vasculitis. Patients were categorized as having 
cytoplasmic and/or proteinase 3-ANCA (thereafter referred to as PR3-ANCA) or 
perinuclear and/or myeloperoxidase-ANCA (thereafter referred to as MPO-ANCA). 
Renal biopsy was classified to the International Working Group of Renal Pathologists 
(IWGRP) class based on paper reports by the individual centers. Available data on B 
cell counts and presence of hypogammaglobulinemia were recorded. 
 
Outcomes: 
The principal outcomes of interest in this cohort were complete remission at 6 months 
and renal recovery after acute dialysis at diagnosis. Other outcomes included ESRD 
during follow up and death within the first 6 months.  
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Study definitions: 
Disease phenotype was defined according to the Chapel Hill Consensus nomenclature. 
Renal function was measured using the 4 variable modification of diet in renal disease 
(MDRD) formula for estimated GFR (e-GFR) (13). Severe renal disease was defined as 
MDRD e-GFR of less than 20 ml/min/m2. ESRD was defined by the ongoing need for 
renal replacement therapy. Hematuria was defined as urinary red blood cell count of 
more than 10 per high power field. Kidney involvement was defined by a diagnostic 
renal biopsy or with the presence of active urine sediment.  Remission was defined as 
stabilization or improvement in serum creatinine, resolution of hematuria and absence 
of extra-renal signs of vasculitis for at least 1 month (1). Relapse was defined as 
occurrence of signs and symptoms of vasculitis in any organ requiring a change in 
immunosuppressive therapy after achieving remission. B cell reconstitution was defined 
as presence of more than 20 CD19 positive B cells per microliter. Depending on use of 
concomitant cyclophosphamide, Group A was defined as patients who received 
glucocorticoids and rituximab only and Group B was defined as patients receiving 
glucocorticoids and rituximab and concomitant cyclophosphamide either administered 
as oral or intravenous pulse cyclophosphamide.  
 
Statistical Analyses: 
Data were tabulated for the full sample, and also divided by treatment group. 
Continuous variables except for eGFR rise were summarized as median [interquartile 
range] and group differences were tested using non-parametric rank sum tests. The 
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variable eGFR rise was presented as mean (standard deviation) and group differences 
were tested using the t-test.  Categorical variables were tabulated as number 
(percentage) and group differences were tested using Fisher exact tests. All tests of 
significance were two sided and differences were considered significant if the p-value 
was less than 0.05. All analyses were done using the Stata statistical software package 
(version 13; College Station, TX).   
 
 
Results: 
 
Patients:  
In total, 37 patients with severe renal disease who met the inclusion criteria were 
identified (between March 2005 and April 2014). The baseline characteristics of the 
entire cohort are shown in Table 1. The median (IQR) age at diagnosis was 61 (55 to 
73) years. Sixty two percent were male and all but one were Caucasian. Twenty two 
patients (59%) were MPO ANCA positive, 13 were PR3 ANCA positive (35%) and 2 
were ANCA negative. Fourteen patients were categorized as GPA and remainder as 
MPA. The majority of them (78%) had a new diagnosis of AAV. The median (IQR) e-
GFR at diagnosis was 13(7 to 16) ml/min/m2 and 15 were dialysis dependent at 
presentation. Of the 27 patients that had a diagnostic renal biopsy, the IWGRP class 
was focal in 3 patients, crescentic in 6 patients, mixed in 12 patients and sclerotic in 6 
patients. The remaining 10 patients were clinically diagnosed. Twenty five patients 
(68%) had extra-renal disease ( 15 with lung, 7 with sinus, 7 with joint, 5 with ear, 4 with 
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eye, 4 with peripheral nerve and 3 with skin involvement)  Eleven  (30%) had alveolar 
hemorrhage. Twelve patients (32%) received rituximab and glucocorticoids (Group A) 
and twenty five patients (68%) received cyclophosphamide, rituximab and 
glucocorticoids (Group B). Glucocorticoid dosing included pulse steroids for 3 days and 
oral prednisone starting at 1 mg/kg/day and weaned according to local protocol. 
Seventeen patients (46%) received plasma exchange. The dosing of RTX was 
375mg/m2 once a week for 4 weeks in 18 patients (49%) and 1000 mg every 2 weeks 
for 2 doses in 19 patients (51%). The median (IQR) follow up was 973 (200 to 1656) 
days. 
 
When stratified by use of concomitant CYC, twelve patients received rituximab and 
glucocorticoids (Group A) and twenty five received cyclophosphamide, rituximab and 
glucocorticoids (Group B). Seven patients received oral cyclophosphamide and 18 
received pulse cyclophosphamide. The median number of pulses in the pulse CYC 
group was 2 (range 1 to 4 ) and the median duration of CYC use in oral CYC group was 
21 days (range 7 to 60 days). The baseline characteristics of both groups are shown in 
Table1. There were no differences in median age (64 yrs vs. 60 yrs, p=0.65), median 
(IQR) baseline e GFR [12 (6 to 16) vs. 13(7 to 16), p = 0.62], the RTX dosing regimen 
used (375 mg/m2 x 4 or 1000 mg x2), use of plasma exchange (33% vs. 52%, p = 0.3) 
or median follow up days between the groups (652 vs. 1050, p = 0.59). Renal biopsies  
categorized by IWGRP class were: Group A (focal in 1 patient, mixed in 4 patients, 
sclerotic in 4 patients and remaining with no biopsy) compared to Group B (focal in 2 
patients, crescentic in 6 patients, mixed in 8 patients, sclerotic in 2 patients and 
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remaining with no biopsy).  Eleven patients had alveolar hemorrhage (3 in Group A and 
8 in Group B). Twelve (2 in Group A and 10 in Group B) did not have extra-renal 
involvement (p=0.26). 
 
Outcomes: 
Thirty two of 33 patients with a minimum follow up of 6 months (97%) achieved disease 
remission at 6 months. The single refractory patient responded to mycophenolate 
mofetil. Among the 15 dialysis dependent patients 10 (67%) experienced renal recovery 
to stop dialysis. The mean (SD) rise in e-GFR at 6 months was 14.5 ml/min/m2 (22). The 
median prednisone (IQR) dose at 6 months was 6 mg (5 to 10).Rituximab was well 
tolerated in both groups and no infusion reactions were reported. A total of 5 (13%) 
patients (1 in Group A and 4 in Group B) did not complete the RTX course, 2 due to lack 
of medical insurance, in two patients RTX was not given due to a ruptured aortic 
aneurysm and transition to palliative care due to CMV viremia and in one patient the 
fourth dose of RTX was not given due to dapsone induced hemolytic anemia. In 18 
patients (49%) with available B cell data, all showed depletion at 6 months. At 12 
months, 2 patients showed B cell reconstitution and the remaining 16 were B cell 
depleted. Among 19 patients who had immunoglobulins checked, 9 had low 
immunoglobulin levels and 10 had normal levels.  There were 4 episodes of leukopenia 
in 4 patients. A total of 10 patients (27%) experienced infections requiring 
hospitalization.  Six patients reached ESRD within the first 6 months and twelve (32%) 
patients reached ESRD during follow up.  Among these 12 patients, 5 were dialysis 
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dependent at presentation, 4 had progressive disease, 2 had disease relapses and 1 
had refractory disease.  
  There were no differences in outcome when groups were stratified according to use of 
concomitant CYC.  All 12 patients in Group A achieved remission compared to 21 of 22 
patients who achieved remission in Group B (p=1.0). There was no significant difference 
in the percentage of dialysis dependent patients who achieved renal recovery between 
the two groups (71% vs. 62%, p=1.00). The mean (SD) rise in e-GFR at 6 months in 
Group A was 17 (20) ml/min/m2 compared to 13ml/min/ m2 (24, p=0.6). The median 
prednisone dose at 6 months was 5 mg in Group A compared to 7.5 mg in Group B (p-
0.04). There were no differences in number of patients reaching ESRD during the follow 
up time or death at 6 months between the groups. There were no deaths in Group A. 
There were 3 deaths in Group B in the first 6 months, one due to ruptured aortic 
aneurysm after 1 month of diagnosis, one due to CMV infection and the cause was 
unknown in one patient.  
Rituximab was well tolerated in both groups and there were no infusion reactions 
reported. There were no differences in episodes of leukopenia or infections requiring 
hospitalization between the groups during the follow up (Table 2). Among 12 patients in 
Group A, one patient suffered from bacterial pneumonia and another patient had herpes 
zoster. Among 25 patients in Group B, 4 patients had bacterial pneumonia, 1 patient 
had sepsis, 1 patient had candida pneumonia, 1 patient had herpes zoster and 1 patient 
had CMV infection. Two episodes of leukopenia occurred in each group. 
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Discussion: 
This retrospective analysis of AAV patients with glomerulonephritis and severe renal 
disease treated with rituximab and glucocorticoids for remission induction demonstrates 
that outcomes are equivalent to those treated with rituximab and glucocorticoids and a 
short course of concomitant cyclophosphamide.  
AAV patients with severe renal disease pose special challenges due to poor response 
to therapy and increased burden of side effects from immunosuppressive therapy. The 
severity of renal dysfunction at diagnosis of AAV portends a poor prognosis for renal 
survival and patient survival. The one year mortality of AAV patients is 11%(7). The 
majority of these early deaths are attributed to therapy related adverse events rather 
than to active vasculitis. The severity of renal dysfunction is the principal predictor of 
therapy related adverse events and mortality. Individuals with impaired renal function 
develop episodes of leukopenia while receiving cyclophosphamide therapy suggesting 
that dose reduction of CYC is required based on GFR. Despite the widespread use of 
CYC in this setting, dose alterations based on GFR are controversial. Strategies that 
eliminate or reduce the use of CYC are needed in patients presenting with severe renal 
dysfunction. Rituximab has been shown to be non-inferior to CYC for remission 
induction in RAVE trial. However, this trial excluded patients with severe renal 
dysfunction. RITUXVAS enrolled patients with severe renal dysfunction but the 
rituximab arm received 2 pulses of IV CYC. Although RAVE and RITUXVAS did not 
show a safety benefit of RTX, there is no convincing evidence that RTX increases the 
frequency of severe infection in AAV and has in fact been used successfully for 
remission induction in the setting of severe infection (14). 
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Our cohort is enriched with patients with MPO-ANCA and patients had more severe 
renal disease at baseline with a significant percentage of them requiring dialysis at entry 
compared to randomized trials using rituximab for inducing remission with comparable 
remission rates. The degree of renal impairment at baseline was similar to MEPEX trial 
patients (15). One third of patients in our cohort had alveolar hemorrhage. Renal 
recovery in dialysis dependent patients in this series is similar to other reported series 
using either a rituximab based regimen or cyclophosphamide based regimen (2, 11, 16) 
and better compared to Chinese cohort of predominantly MPO ANCA patients treated 
with cyclophosphamide and glucocorticoids(17).  In this context, it should be noted that 
despite the presence of severe renal disease, only 46% of patients in our cohort 
received plasma exchange. The median prednisone dose at 6 months in our cohort is 
comparable to RITUXVAS and was significantly lower in the group that received 
rituximab only. About a third of patients in this cohort experienced infections requiring 
hospitalization which is higher than reported in RAVE and RITUXVAS (11, 18). This 
may be related to the severity of renal disease in this cohort and use of standard doses 
of glucocorticoids. The mortality is lower compared to other reported series which 
included AAV patients with severe renal disease(2, 11, 17) and similar to another series 
using intravenous cyclophosphamide and plasma exchange for dialysis dependent AAV 
patients(16). The lower mortality may be due to minimization or avoidance of 
cyclophosphamide. 
Our study is limited by its retrospective design and small sample size. There is 
significant heterogeneity in treatment regimens with regard to use of plasma exchange 
and dosing of glucocorticoids and CYC across centers. Due to relatively short follow up, 
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the duration of sustained remission and impact on long term renal function is not evident 
from this study. Although proteinuria is an important marker for damage in AAV, we did 
not have information on protein quantification for majority of patients. Not all patients in 
our cohort had biopsy confirmed GN and the renal biopsies were classified into the 
IWGRP class based on pathology reports and were not centrally read. We lack on our 
ability to comment on the nature of cell infiltrates due to lack of data on immunostaining 
for markers of B cells, T cells and plasma cells. This is relevant in light of recent study 
from RITUXVAS patients which correlates renal outcome at one year follow up with T 
cell tubulitis and the possibility that B cell targeted therapy may not control this arm of 
the pathogenesis(19). 
This retrospective multi-center study demonstrates no added benefit of a short course of 
CYC for remission induction in AAV patients with glomerulonephritis and severe renal 
disease treated with a single course of rituximab and glucocorticoids. An open-label, 
randomized, controlled study is under way (PEXIVAS; NCT00987389), which aims to 
determine the role of plasma exchange and glucocorticoid dosing in severe AAV. In this 
trial, enrolled participants have an e-GFR less than 50 ml/min/m2 and rituximab is 
permitted for remission induction and therefore the trial may provide additional data on 
efficacy and safety of rituximab.  Further prospective randomized trials are needed to 
confirm these findings in this cohort of AAV patients with severe renal disease who are 
at risk for early mortality from therapy related adverse events.  
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Table1: Baseline characteristics of AAV patients with severe renal disease stratified by 
use of cyclophosphamide 
 Entire cohort 
(n=37) 
Group A(n=12) Group B(n=25) P value 
Age at diagnosis (yrs), 
median(IQR) 
61(55 to 73) 64(37 to 73) 60(55 to73) 0.65 
Gender ,M:F 23:14 7:5 16:9 1.0 
ANCA type: n 
PR3 
MPO 
Negative  
 
13 
22 
2 
 
4 
6 
2 
 
9 
16 
0 
0.19 
New diagnosis, n (%) 29 (78) 11 (92) 18 (72) 0.23 
e-GFR at entry 
(ml/min) median (IQR) 
13 (7 to 16) 12 (6 to 16) 13 (7 to 16) 0.62 
Dialysis dependent at 
entry (n) (%) 
15 (40%) 7 (58%) 8 (32%) 0.16 
Use of PLEX, n (%) 17 (46%) 4 (33%) 13 (52) 0.32 
Extra-renal disease, n 
(%) 
25 (68%) 10 (83%) 15 (60%) 0.26 
Alveolar hemorrhage, 
n (%) 
11 (30%) 3 (25%) 8 (32%) 1.0 
RTX dosing 
375 mg/m2 q week for 
4 weeks, n (%) 
1000 mg x 2 doses, n 
(%) 
 
18(49) 
 
19 (51) 
 
6(50) 
 
6 (50) 
 
12 (48) 
 
13 (52) 
 
 
1.0 
16 
 
Cyclophosphamide 
use 
Oral(n) 
Pulse(n) 
 
 
7 
18 
 
 
NA 
 
 
7 
18 
 
Clinical site*: 
1 
2 
3 
4 
5 
6 
 
11 
2 
4 
7 
7 
6 
 
4 
1 
0 
1 
3 
3 
 
7 
1 
4 
6 
4 
3 
 
Follow up time, 
median days (IQR) 
973 (200 to 
1656) 
652 (325 to 
1518) 
1050 (135 to 
2367) 
0.59 
*1=Johns Hopkins, Baltimore, U.S.A., 2=Columbia University, New York, U.S.A., 
3=Charles University, Prague, 4= Linkoping University Sweden, 5=University of 
Birmingham, U.K., 6=Cambridge University hospital, U.K. 
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Table2: Outcomes of patients with severe AAV treated with RTX + GC (Group A) vs. 
RTX+ CYC +GC (Group B) 
Outcomes Group A(n=12) Group B (n=25) P value 
Remission n (%) (n=34) 11(100%) 21 (95%) 1.0 
Median 6 month 
Prednisone dose 
(mg)(range)  
5(0 to 6) 7.5 (5 to 10) 0.04 
Mean GFR rise at 6 
months (SD) 
18( 20) 13 (24) 0.6 
Renal recovery,  n 
%(n=15) 
5 (71) 5 (62) 1.0 
Infections, n (%)  2 (17) 8 (32) 0.44 
Leukopenia, n (%)  2 (17) 2(8) 0.58 
ESRD, n (%)  4 (33) 8 (32) 1.0 
Death in the first 6 
months  
0 (0) 3(12) 0.54 
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